Unknown PHASE2 INTERVENTIONAL 1-arm NCT02976740

SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

A Prospective Multi-center Phase II Study: Assessment of the Safety and Abscopal Effects of SBRT Combination With rhGM-CSF and Thymosin Alpha 1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy

Sponsor: The First Affiliated Hospital of Xiamen University

Conditions Lung Cancer Metastatic

Interventions Immunological Agent Immunological Factors SBRT

Updated 7 times since 2017 Last updated: Nov 28, 2016 Started: Nov 30, 2016 Primary completion: Jun 30, 2019 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02976740, this PHASE2 trial focuses on Lung Cancer Metastatic and remains ongoing. Sponsored by The First Affiliated Hospital of Xiamen University, it has been updated 7 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jan 2020 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Jan 2020 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The First Affiliated Hospital of Xiamen University

Data source: The First Affiliated Hospital of Xiamen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xiamen, China